IGC Pharma, Inc.
IGC$30M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPOTOMAC70 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 30, 2026
7wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
IGC-AD1-Active Phase 2 Results Expected
Mar 30, 2026IGC-AD1-Active164
Primary completion for IGC-AD1-Active trial (NCT05543681) in Alzheimer Disease
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
IGC-AD1-Active | Phase 2 | Alzheimer Disease | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
IGC News